CN107827966B - Antibacterial peptide KR-22 and application thereof - Google Patents
Antibacterial peptide KR-22 and application thereof Download PDFInfo
- Publication number
- CN107827966B CN107827966B CN201710973506.4A CN201710973506A CN107827966B CN 107827966 B CN107827966 B CN 107827966B CN 201710973506 A CN201710973506 A CN 201710973506A CN 107827966 B CN107827966 B CN 107827966B
- Authority
- CN
- China
- Prior art keywords
- antimicrobial peptide
- peptide
- antibacterial
- antimicrobial
- diarrhea
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003910 polypeptide antibiotic agent Substances 0.000 title claims abstract description 57
- 108700042778 Antimicrobial Peptides Proteins 0.000 claims abstract description 57
- 102000044503 Antimicrobial Peptides Human genes 0.000 claims abstract description 57
- 206010012735 Diarrhoea Diseases 0.000 claims abstract description 25
- 238000011282 treatment Methods 0.000 claims abstract description 9
- 241000894006 Bacteria Species 0.000 claims abstract description 7
- 238000002360 preparation method Methods 0.000 claims abstract description 7
- 229940124350 antibacterial drug Drugs 0.000 claims abstract description 4
- 239000003814 drug Substances 0.000 claims abstract description 4
- 229940079593 drug Drugs 0.000 claims abstract description 4
- 230000003832 immune regulation Effects 0.000 claims abstract description 4
- 241000192125 Firmicutes Species 0.000 claims abstract description 3
- 208000015181 infectious disease Diseases 0.000 claims abstract description 3
- 230000002265 prevention Effects 0.000 claims abstract description 3
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 23
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 16
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 8
- 229920001184 polypeptide Polymers 0.000 abstract description 6
- 239000006041 probiotic Substances 0.000 abstract description 4
- 235000018291 probiotics Nutrition 0.000 abstract description 4
- 238000013461 design Methods 0.000 abstract description 3
- 238000003786 synthesis reaction Methods 0.000 abstract description 3
- 125000000539 amino acid group Chemical group 0.000 abstract description 2
- 230000015572 biosynthetic process Effects 0.000 abstract description 2
- 125000002091 cationic group Chemical group 0.000 abstract description 2
- 238000001228 spectrum Methods 0.000 abstract description 2
- 230000003612 virological effect Effects 0.000 abstract 1
- 210000003743 erythrocyte Anatomy 0.000 description 13
- 101000741302 Bungarus fasciatus Cathelicidin-related antimicrobial peptide Bf-CRAMP Proteins 0.000 description 9
- 239000002609 medium Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 206010018910 Haemolysis Diseases 0.000 description 7
- 241000282898 Sus scrofa Species 0.000 description 7
- 230000001580 bacterial effect Effects 0.000 description 7
- 230000003013 cytotoxicity Effects 0.000 description 7
- 231100000135 cytotoxicity Toxicity 0.000 description 7
- 230000008588 hemolysis Effects 0.000 description 7
- 108090000695 Cytokines Proteins 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 239000013642 negative control Substances 0.000 description 5
- 230000003115 biocidal effect Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 239000012224 working solution Substances 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 3
- 241000282887 Suidae Species 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000002949 hemolytic effect Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 210000005087 mononuclear cell Anatomy 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- VCSABYLVNWQYQE-UHFFFAOYSA-N Ala-Lys-Lys Natural products NCCCCC(NC(=O)C(N)C)C(=O)NC(CCCCN)C(O)=O VCSABYLVNWQYQE-UHFFFAOYSA-N 0.000 description 2
- 241000256019 Antheraea yamamai Species 0.000 description 2
- CLICCYPMVFGUOF-IHRRRGAJSA-N Arg-Lys-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O CLICCYPMVFGUOF-IHRRRGAJSA-N 0.000 description 2
- 241000272081 Bungarus fasciatus Species 0.000 description 2
- 101800003223 Cecropin-A Proteins 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- IPTUBUUIFRZMJK-ACRUOGEOSA-N Lys-Phe-Phe Chemical compound C([C@H](NC(=O)[C@@H](N)CCCCN)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 IPTUBUUIFRZMJK-ACRUOGEOSA-N 0.000 description 2
- 241000410394 Odorrana grahami Species 0.000 description 2
- RBRNEFJTEHPDSL-ACRUOGEOSA-N Phe-Phe-Lys Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(O)=O)NC(=O)[C@@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 RBRNEFJTEHPDSL-ACRUOGEOSA-N 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 108010047495 alanylglycine Proteins 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- CYDMQBQPVICBEU-UHFFFAOYSA-N chlorotetracycline Natural products C1=CC(Cl)=C2C(O)(C)C3CC4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-UHFFFAOYSA-N 0.000 description 2
- 229960004475 chlortetracycline Drugs 0.000 description 2
- CYDMQBQPVICBEU-XRNKAMNCSA-N chlortetracycline Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-XRNKAMNCSA-N 0.000 description 2
- 235000019365 chlortetracycline Nutrition 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 108010010147 glycylglutamine Proteins 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 108010009298 lysylglutamic acid Proteins 0.000 description 2
- 108010054155 lysyllysine Proteins 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 208000026775 severe diarrhea Diseases 0.000 description 2
- FJVAQLJNTSUQPY-CIUDSAMLSA-N Ala-Ala-Lys Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@H](C(O)=O)CCCCN FJVAQLJNTSUQPY-CIUDSAMLSA-N 0.000 description 1
- PNALXAODQKTNLV-JBDRJPRFSA-N Ala-Ile-Ala Chemical compound C[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O PNALXAODQKTNLV-JBDRJPRFSA-N 0.000 description 1
- VCSABYLVNWQYQE-SRVKXCTJSA-N Ala-Lys-Lys Chemical compound NCCCC[C@H](NC(=O)[C@@H](N)C)C(=O)N[C@@H](CCCCN)C(O)=O VCSABYLVNWQYQE-SRVKXCTJSA-N 0.000 description 1
- VBFJESQBIWCWRL-DCAQKATOSA-N Arg-Ala-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCCNC(N)=N VBFJESQBIWCWRL-DCAQKATOSA-N 0.000 description 1
- GXXWTNKNFFKTJB-NAKRPEOUSA-N Arg-Ile-Ser Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(O)=O GXXWTNKNFFKTJB-NAKRPEOUSA-N 0.000 description 1
- PSLSTUMPZILTAH-BYULHYEWSA-N Asp-Gly-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)CNC(=O)[C@@H](N)CC(O)=O PSLSTUMPZILTAH-BYULHYEWSA-N 0.000 description 1
- KBJVTFWQWXCYCQ-IUKAMOBKSA-N Asp-Thr-Ile Chemical compound [H]N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O KBJVTFWQWXCYCQ-IUKAMOBKSA-N 0.000 description 1
- 239000004099 Chlortetracycline Substances 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000272060 Elapidae Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- WMOMPXKOKASNBK-PEFMBERDSA-N Gln-Asn-Ile Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O WMOMPXKOKASNBK-PEFMBERDSA-N 0.000 description 1
- CUXJIASLBRJOFV-LAEOZQHASA-N Glu-Gly-Ile Chemical compound [H]N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(O)=O CUXJIASLBRJOFV-LAEOZQHASA-N 0.000 description 1
- IDOGEHIWMJMAHT-BYPYZUCNSA-N Gly-Gly-Cys Chemical compound NCC(=O)NCC(=O)N[C@@H](CS)C(O)=O IDOGEHIWMJMAHT-BYPYZUCNSA-N 0.000 description 1
- SWQALSGKVLYKDT-UHFFFAOYSA-N Gly-Ile-Ala Natural products NCC(=O)NC(C(C)CC)C(=O)NC(C)C(O)=O SWQALSGKVLYKDT-UHFFFAOYSA-N 0.000 description 1
- JPAACTMBBBGAAR-HOTGVXAUSA-N Gly-Leu-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](NC(=O)CN)CC(C)C)C(O)=O)=CNC2=C1 JPAACTMBBBGAAR-HOTGVXAUSA-N 0.000 description 1
- VEPBEGNDJYANCF-QWRGUYRKSA-N Gly-Lys-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)CN)CCCCN VEPBEGNDJYANCF-QWRGUYRKSA-N 0.000 description 1
- GGLIDLCEPDHEJO-BQBZGAKWSA-N Gly-Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)CN GGLIDLCEPDHEJO-BQBZGAKWSA-N 0.000 description 1
- JYPCXBJRLBHWME-IUCAKERBSA-N Gly-Pro-Arg Chemical compound NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCNC(N)=N)C(O)=O JYPCXBJRLBHWME-IUCAKERBSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- DXUJSRIVSWEOAG-NAKRPEOUSA-N Ile-Arg-Cys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CS)C(=O)O)N DXUJSRIVSWEOAG-NAKRPEOUSA-N 0.000 description 1
- CYHJCEKUMCNDFG-LAEOZQHASA-N Ile-Gln-Gly Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)NCC(=O)O)N CYHJCEKUMCNDFG-LAEOZQHASA-N 0.000 description 1
- UIEZQYNXCYHMQS-BJDJZHNGSA-N Ile-Lys-Ala Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)O)N UIEZQYNXCYHMQS-BJDJZHNGSA-N 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- 241000880493 Leptailurus serval Species 0.000 description 1
- MYGQXVYRZMKRDB-SRVKXCTJSA-N Leu-Asp-Lys Chemical compound CC(C)C[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCCCN MYGQXVYRZMKRDB-SRVKXCTJSA-N 0.000 description 1
- YVKSMSDXKMSIRX-GUBZILKMSA-N Leu-Glu-Asn Chemical compound [H]N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O YVKSMSDXKMSIRX-GUBZILKMSA-N 0.000 description 1
- PJWOOBTYQNNRBF-BZSNNMDCSA-N Leu-Phe-Lys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CCCCN)C(=O)O)N PJWOOBTYQNNRBF-BZSNNMDCSA-N 0.000 description 1
- DFXQCCBKGUNYGG-GUBZILKMSA-N Lys-Gln-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCCCN DFXQCCBKGUNYGG-GUBZILKMSA-N 0.000 description 1
- QBEPTBMRQALPEV-MNXVOIDGSA-N Lys-Ile-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H](N)CCCCN QBEPTBMRQALPEV-MNXVOIDGSA-N 0.000 description 1
- YDDDRTIPNTWGIG-SRVKXCTJSA-N Lys-Lys-Ser Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(O)=O YDDDRTIPNTWGIG-SRVKXCTJSA-N 0.000 description 1
- AFLBTVGQCQLOFJ-AVGNSLFASA-N Lys-Pro-Arg Chemical compound NCCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(O)=O AFLBTVGQCQLOFJ-AVGNSLFASA-N 0.000 description 1
- YUTZYVTZDVZBJJ-IHPCNDPISA-N Lys-Trp-Lys Chemical compound C1=CC=C2C(C[C@H](NC(=O)[C@@H](N)CCCCN)C(=O)N[C@@H](CCCCN)C(O)=O)=CNC2=C1 YUTZYVTZDVZBJJ-IHPCNDPISA-N 0.000 description 1
- VWPJQIHBBOJWDN-DCAQKATOSA-N Lys-Val-Ala Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(O)=O VWPJQIHBBOJWDN-DCAQKATOSA-N 0.000 description 1
- VKCPHIOZDWUFSW-ONGXEEELSA-N Lys-Val-Gly Chemical compound OC(=O)CNC(=O)[C@H](C(C)C)NC(=O)[C@@H](N)CCCCN VKCPHIOZDWUFSW-ONGXEEELSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010087066 N2-tryptophyllysine Proteins 0.000 description 1
- BQVUABVGYYSDCJ-UHFFFAOYSA-N Nalpha-L-Leucyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)C(N)CC(C)C)C(O)=O)=CNC2=C1 BQVUABVGYYSDCJ-UHFFFAOYSA-N 0.000 description 1
- AXIOGMQCDYVTNY-ACRUOGEOSA-N Phe-Phe-Leu Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 AXIOGMQCDYVTNY-ACRUOGEOSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- WTUJZHKANPDPIN-CIUDSAMLSA-N Ser-Ala-Lys Chemical compound C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)[C@H](CO)N WTUJZHKANPDPIN-CIUDSAMLSA-N 0.000 description 1
- LRZLZIUXQBIWTB-KATARQTJSA-N Ser-Lys-Thr Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O LRZLZIUXQBIWTB-KATARQTJSA-N 0.000 description 1
- FVFUOQIYDPAIJR-XIRDDKMYSA-N Ser-Trp-Leu Chemical compound CC(C)C[C@@H](C(=O)O)NC(=O)[C@H](CC1=CNC2=CC=CC=C21)NC(=O)[C@H](CO)N FVFUOQIYDPAIJR-XIRDDKMYSA-N 0.000 description 1
- 241000270295 Serpentes Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- GARULAKWZGFIKC-RWRJDSDZSA-N Thr-Gln-Ile Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O GARULAKWZGFIKC-RWRJDSDZSA-N 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- ZHZLQVLQBDBQCQ-WDSOQIARSA-N Trp-Lys-Arg Chemical compound C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N ZHZLQVLQBDBQCQ-WDSOQIARSA-N 0.000 description 1
- UHXOYRWHIQZAKV-SZMVWBNQSA-N Trp-Pro-Arg Chemical compound O=C([C@H](CC=1C2=CC=CC=C2NC=1)N)N1CCC[C@H]1C(=O)N[C@@H](CCCN=C(N)N)C(O)=O UHXOYRWHIQZAKV-SZMVWBNQSA-N 0.000 description 1
- WGHVMKFREWGCGR-SRVKXCTJSA-N Val-Arg-Arg Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N WGHVMKFREWGCGR-SRVKXCTJSA-N 0.000 description 1
- UKEVLVBHRKWECS-LSJOCFKGSA-N Val-Ile-Gly Chemical compound CC[C@H](C)[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](C(C)C)N UKEVLVBHRKWECS-LSJOCFKGSA-N 0.000 description 1
- YMTOEGGOCHVGEH-IHRRRGAJSA-N Val-Lys-Lys Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(O)=O YMTOEGGOCHVGEH-IHRRRGAJSA-N 0.000 description 1
- PGQUDQYHWICSAB-NAKRPEOUSA-N Val-Ser-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)N PGQUDQYHWICSAB-NAKRPEOUSA-N 0.000 description 1
- AEFJNECXZCODJM-UWVGGRQHSA-N Val-Val-Gly Chemical compound CC(C)[C@H]([NH3+])C(=O)N[C@@H](C(C)C)C(=O)NCC([O-])=O AEFJNECXZCODJM-UWVGGRQHSA-N 0.000 description 1
- 206010051511 Viral diarrhoea Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 108010076324 alanyl-glycyl-glycine Proteins 0.000 description 1
- -1 aromatic amino acids Chemical class 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- HCQPHKMLKXOJSR-IRCPFGJUSA-N cecropin-a Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(N)=O)[C@@H](C)CC)C(C)C)[C@@H](C)CC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](N)CCCCN)C1=CC=CC=C1 HCQPHKMLKXOJSR-IRCPFGJUSA-N 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- JYPCXBJRLBHWME-UHFFFAOYSA-N glycyl-L-prolyl-L-arginine Natural products NCC(=O)N1CCCC1C(=O)NC(CCCN=C(N)N)C(O)=O JYPCXBJRLBHWME-UHFFFAOYSA-N 0.000 description 1
- 108010025801 glycyl-prolyl-arginine Proteins 0.000 description 1
- 108010037850 glycylvaline Proteins 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 108010034529 leucyl-lysine Proteins 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 108010043322 lysyl-tryptophyl-alpha-lysine Proteins 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
本发明公开了一种抗菌肽,名为KR‑22,其全序列为:KFFRKLWKRVRRAAKEFFKWPR,SEQ ID NO:1。所述抗菌肽KR‑22为人工设计合成的活性多肽,KR‑22包含22个氨基酸残基,分子量为2695.3Da,等电点为8.97,净电荷为+9。所述的抗菌肽的用途,用于制备治疗革兰氏阴性菌或者革兰氏阳性菌感染的广谱抗菌药物。所述的抗菌肽的用途,用于制备改善免疫调控药物。所述的抗菌肽的用途,用于制备断奶腹泻仔猪的治疗或预防制剂。本发明的抗菌肽KR‑22为α螺旋阳离子多肽,具有肽链长度较短、稳定性较好、人工合成方便的特点。抗菌肽KR‑22具有净电荷高、抗菌谱广、杀菌作用强、对益生菌无杀菌作用等优点,同时具有溶血活性低和细胞毒性小、能发挥免疫调控作用从而降低炎症等特点,还可缓解病毒性仔猪腹泻。
The invention discloses an antimicrobial peptide named KR‑22, whose full sequence is: KFFRKLWKRVRRAAKEFFKWPR, SEQ ID NO:1. The antimicrobial peptide KR‑22 is an active polypeptide synthesized by artificial design. KR‑22 contains 22 amino acid residues, has a molecular weight of 2695.3 Da, an isoelectric point of 8.97, and a net charge of +9. The use of the antimicrobial peptide is used to prepare broad-spectrum antibacterial drugs for treating Gram-negative bacteria or Gram-positive bacteria infections. The use of the antibacterial peptide is used to prepare drugs for improving immune regulation. The use of the antimicrobial peptide is used to prepare a treatment or prevention preparation for piglets with weaning diarrhea. The antimicrobial peptide KR-22 of the present invention is an α-helical cationic polypeptide, which has the characteristics of short peptide chain length, good stability and convenient artificial synthesis. The antibacterial peptide KR‑22 has the advantages of high net charge, broad antibacterial spectrum, strong bactericidal effect, and no bactericidal effect on probiotics. Relief of viral piglet diarrhea.
Description
技术领域technical field
本发明属于生物医学技术领域,特别是涉及抗菌肽KR-22及其应用。The invention belongs to the technical field of biomedicine, and in particular relates to antibacterial peptide KR-22 and its application.
背景技术Background technique
抗菌肽是广泛存在于以自然界生物体中的一种多肽类物质,其来源十分广泛,目前已在植物、昆虫、两栖类动物、哺乳动物、海洋生物、细菌、病毒等生物体中发现了1700多种抗菌肽,抗菌肽是重要的先天免疫分子,具有广谱抗菌活性、破膜杀菌机制以及不易产生耐药性等特点。同时,抗菌肽被认为是最具潜力的抗生素替代品,所以抗菌肽的研发将成为寻找抗生素替代品的重要突破口,并且抗菌肽在治疗仔猪腹泻方面的研究为抗菌肽在实际应用上提供了重要的参考价值。目前,部分抗菌活性较好的抗菌肽如C-BF、P-OG1存在一定的细胞毒性,如何增强其抗菌活性和降低细胞毒性成为研究热点之一,而抗菌肽分子改良是该研究热点较为常用的手段。Antimicrobial peptides are a kind of polypeptide substances that widely exist in natural organisms, and their sources are very extensive. At present, 1700 have been found in organisms such as plants, insects, amphibians, mammals, marine organisms, bacteria, and viruses. A variety of antimicrobial peptides, antimicrobial peptides are important innate immune molecules, with broad-spectrum antibacterial activity, membrane-breaking bactericidal mechanism, and resistance to drug resistance. At the same time, antimicrobial peptides are considered to be the most potential alternatives to antibiotics, so the research and development of antimicrobial peptides will become an important breakthrough in finding alternatives to antibiotics, and the research on antimicrobial peptides in the treatment of piglet diarrhea provides important information for the practical application of antimicrobial peptides. reference value. At present, some antibacterial peptides with better antibacterial activity, such as C-BF and P-OG1, have certain cytotoxicity. How to enhance their antibacterial activity and reduce cytotoxicity has become one of the research hotspots, and the molecular improvement of antimicrobial peptides is a common research hotspot. s method.
发明内容Contents of the invention
为了克服现有技术的不足,本发明要解决的技术问题是提供一种抗菌肽KR-22及其用途。In order to overcome the deficiencies of the prior art, the technical problem to be solved by the present invention is to provide an antimicrobial peptide KR-22 and its application.
一种抗菌肽,名为KR-22,其全序列为:KFFRKLWKRVRRAAKEFFKWPR,SEQ ID NO:1。An antimicrobial peptide named KR-22, its full sequence is: KFFRKLWKRVRRAAKEFFKWPR, SEQ ID NO:1.
所述抗菌肽 KR-22为人工设计合成的活性多肽,KR-22包含 22 个氨基酸残基,分子量为 2695.3Da,等电点为 8.97,净电荷为 +9。The antibacterial peptide KR-22 is an active polypeptide synthesized by artificial design. KR-22 contains 22 amino acid residues, has a molecular weight of 2695.3Da, an isoelectric point of 8.97, and a net charge of +9.
所述的抗菌肽的用途,用于制备治疗革兰氏阴性菌或者革兰氏阳性菌感染的广谱抗菌药物。The use of the antimicrobial peptide is used to prepare broad-spectrum antibacterial drugs for treating Gram-negative bacteria or Gram-positive bacteria infections.
所述的抗菌肽的用途,用于制备改善免疫调控药物。The use of the antibacterial peptide is used to prepare drugs for improving immune regulation.
所述的抗菌肽的用途,用于制备断奶腹泻仔猪的治疗或预防制剂。The use of the antimicrobial peptide is used to prepare a treatment or prevention preparation for piglets with weaning diarrhea.
本发明的有益效果:Beneficial effects of the present invention:
本发明的抗菌肽 KR-22为α螺旋阳离子多肽,具有肽链长度较短、稳定性较好、人工合成方便的特点。抗菌肽KR-22具有净电荷高、抗菌谱广、杀菌作用强、对益生菌无杀菌作用等优点,同时具有溶血活性低和细胞毒性小、能发挥免疫调控作用从而降低炎症等特点。抗菌肽KR-22还对病毒有抑制作用,可缓解病毒性仔猪腹泻。The antimicrobial peptide KR-22 of the present invention is an α-helical cationic polypeptide, which has the characteristics of short peptide chain length, good stability and convenient artificial synthesis. The antibacterial peptide KR-22 has the advantages of high net charge, broad antibacterial spectrum, strong bactericidal effect, and no bactericidal effect on probiotics. It also has the characteristics of low hemolytic activity and low cytotoxicity, and can exert immune regulation to reduce inflammation. The antimicrobial peptide KR-22 also has an inhibitory effect on viruses and can relieve viral diarrhea in piglets.
附图说明Description of drawings
下面结合附图对本发明的具体实施方式作进一步详细说明。The specific implementation manners of the present invention will be described in further detail below in conjunction with the accompanying drawings.
图1是不同溶度的抗菌肽KR-22对猪红细胞的溶血率对比图,以上结果为6次独立重复实验平均值。Figure 1 is a comparison chart of the hemolysis rate of porcine red blood cells by antimicrobial peptide KR-22 with different solubility, and the above results are the average value of 6 independent repeated experiments.
图2是抗菌肽KR-22对猪PMBCs的细胞毒性对比图,LDH表示乳酸脱氢酶,以上结果为6次独立重复实验平均值。Figure 2 is a comparison chart of the cytotoxicity of the antimicrobial peptide KR-22 on porcine PMBCs, LDH represents lactate dehydrogenase, and the above results are the average values of 6 independent repeated experiments.
图3是抗菌肽KR-22对猪红细胞的增殖率,以上结果为6次独立重复实验平均值。Figure 3 shows the proliferation rate of the antibacterial peptide KR-22 on porcine erythrocytes, and the above results are the average values of 6 independent repeated experiments.
具体实施方式Detailed ways
实施例 1、抗菌肽KR-22 的制备Embodiment 1, the preparation of antimicrobial peptide KR-22
蛇源抗菌肽Cathelicidin-BF(C-BF),具有广谱的抗菌活性,对革兰氏阴性菌特别是能够致仔猪腹泻的大肠杆菌具有较好的作用,最小抑菌浓度(MIC)在8-64 μg/mL之间。本发明以 C-BF 为模板,通过分子设计对其进行改良,改良方式包括,替换模板肽氨基酸、改变肽链长度、改变分子疏水性以及增加芳香族氨基酸比例等,通过化学合成方式合成改良肽。Cathelicidin-BF (C-BF), a snake-derived antimicrobial peptide, has broad-spectrum antibacterial activity and has a good effect on Gram-negative bacteria, especially Escherichia coli that can cause diarrhea in piglets. The minimum inhibitory concentration (MIC) is 8 -64 μg/mL. The present invention uses C-BF as a template, and improves it through molecular design. The improvement method includes replacing the template peptide amino acid, changing the length of the peptide chain, changing the hydrophobicity of the molecule, and increasing the proportion of aromatic amino acids, etc., and synthesizing the improved peptide by chemical synthesis. .
通过NCBI蛋白数据库搜寻比对所找到的与本发明的抗菌肽KR-22较类似的蛙源抗菌肽P-OG1,同时文献查找到的抗菌活性较强的多肽虫源抗菌肽Cecropin A和CP-1,结合模板肽C-BF进行对比检测。The frog-derived antimicrobial peptide P-OG1, which is similar to the antibacterial peptide KR-22 of the present invention, was found by searching and comparing the NCBI protein database. At the same time, the peptides with strong antibacterial activity found in the literature Cecropin A and CP- 1. Combined with the template peptide C-BF for comparative detection.
涉及到多肽的序列具体如下:The sequence related to the polypeptide is as follows:
1)KR-22其全序列为:KFFRKLWKRVRRAAKEFFKWPR,SEQ ID NO:1;1) The full sequence of KR-22 is: KFFRKLWKRVRRAAKEFFKWPR, SEQ ID NO: 1;
2)金环蛇(Bungarus fasciatus)抗菌肽(模板肽) C-BF:KFFRKLKKSVKKRAKEFFKKPRVIGVSIPF,SEQ ID NO:2;2) Bungarus fasciatus antimicrobial peptide (template peptide) C-BF:KFFRKLKKSVKKRAKEFFKKPRVIGVSIPF, SEQ ID NO:2;
3)无指盘臭蛙(Rana grahami)抗菌肽P-OG1:GLWDTIKQAGKKFFLNVLDKIRCKVAGGCRT,SEQ ID NO:3;3) Rana grahami antimicrobial peptide P-OG1: GLWDTIKQAGKKFFLNVLDKIRCKVAGGCRT, SEQ ID NO: 3;
4)天蚕(Antheraea yamamai Guerin-Meneville)抗菌肽Cecropin A(CA):KWKLFKKIEKVGQNIRDGIIKAGPAVAVVGQATQIAK,SEQ ID NO:4;4) Antheraea yamamai Guerin-Meneville antimicrobial peptide Cecropin A(CA): KWKLFKKIEKVGQNIRDGIIKAGPAVAVVGQATQIAK, SEQ ID NO: 4;
5)野猪(Sus scrofa)抗菌肽CP-1:SWLSKTAKKLENSAKKRISEGIAIAIQGGPR,SEQ IDNO:5。5) Wild boar (Sus scrofa) antimicrobial peptide CP-1: SWLSKTAKKLENSAKKRISEGIAAIIQGGPR, SEQ ID NO:5.
实施例2 、抗菌肽KR-22的抗菌实验(MIC)Example 2. Antibacterial test (MIC) of antimicrobial peptide KR-22
将细菌接种于MH肉汤固体培养基上,培养至长出单菌落,挑取单菌落接种于 3mLMH肉汤培养基中,放入摇床培养至菌液浑浊,取 30μL 菌悬液转接至 3mL 新鲜 MH 肉汤培养基中,恒温震荡培养至OD600=0.5左右;取菌悬液 10μL转接至10mL新鲜MH肉汤培养基中涡旋混匀,控制浓度在1×105—5×105 CFU/mL,用于 MIC的测定;将抗菌肽进行梯度稀释,至终浓度为1280、640、320、160、80、40、20、10、5、2.5、1.25、0.625、0.3125(μg/mL),共13个系列浓度的肽稀释液,将抗生素(金霉素)进行梯度稀释,至终浓度320、160、80、40、20、10、5、2.5、1.25、0.625、0.3125(μg/mL),共11个系列浓度的抗生素稀释液;先向无菌96孔圆底板加入90μL制备好的细菌悬液,再逐一加入10μL相应浓度的肽稀释液或者抗生素稀释液,每种抗菌物质做三个重复,另外设阳性对照孔为不加抗菌物质,只加100μL菌悬液,阴性对照孔加100μL LB培养基;将96孔板置于37℃生化培养箱中保湿静置培养18-24小时,培养完后观察各孔底部是否有细菌沉淀产生,无肉眼可见细菌沉淀的最小浓度可判定为抗菌物质的MIC。Inoculate the bacteria on the MH broth solid medium, cultivate until a single colony grows, pick a single colony and inoculate it in 3mL MH broth medium, put it into a shaker and culture until the bacterial solution is turbid, take 30μL of the bacterial suspension and transfer it to In 3mL of fresh MH broth medium, shake culture at constant temperature until OD600=0.5; take 10μL of bacterial suspension and transfer to 10mL of fresh MH broth medium, vortex and mix well, and control the concentration at 1×10 5 —5×10 5 CFU/mL for the determination of MIC; the antimicrobial peptides were serially diluted to a final concentration of 1280, 640, 320, 160, 80, 40, 20, 10, 5, 2.5, 1.25, 0.625, 0.3125 (μg/ mL), a total of 13 serial concentrations of peptide dilutions, the antibiotic (chlortetracycline) was serially diluted to a final concentration of 320, 160, 80, 40, 20, 10, 5, 2.5, 1.25, 0.625, 0.3125 (μg /mL), a total of 11 serial concentrations of antibiotic dilutions; first add 90 μL of the prepared bacterial suspension to a sterile 96-well round bottom plate, and then add 10 μL of the corresponding concentration of peptide dilution or antibiotic dilution one by one, each antibacterial substance Do three repetitions. In addition, set the positive control well without adding antibacterial substances, only add 100 μL of bacterial suspension, and add 100 μL of LB medium to the negative control well; place the 96-well plate in a biochemical incubator at 37 ° C to keep it moist and culture for 18- After 24 hours of cultivation, observe whether there is bacterial precipitation at the bottom of each well. The minimum concentration without visible bacterial precipitation can be determined as the MIC of the antibacterial substance.
表1Table 1
注:MIC是minimum inhibitory concentration缩写,指最低抑菌浓度,最低抑菌浓度是测量抗菌药物的抗菌活性大小的一个指标,指在体外培养细菌18至24小时后能抑制培养基内病原菌生长的最低药物浓度。数值越小,说明抑菌效果越好。Note: MIC is the abbreviation of minimum inhibitory concentration, which refers to the minimum inhibitory concentration, which is an index for measuring the antibacterial activity of antibacterial drugs, and refers to the lowest value that can inhibit the growth of pathogenic bacteria in the medium after culturing bacteria in vitro for 18 to 24 hours drug concentration. The smaller the value, the better the antibacterial effect.
检测结果如下:如表1所示,P-OG1具有一定的抗菌活性,CA、C-BF、CP-1的抗菌活性较好,但抗菌活性不如抗菌肽KR-22,金霉素抗菌效果较好,但对益生菌具有较高的杀伤作用,而KR-22对益生菌抑制效果较弱。然而P-OG1呈剂量依赖效应,溶血率和细胞毒性随浓度升高而升高,安全性远低于抗菌肽KR-22(见图3)。The test results are as follows: as shown in Table 1, P-OG1 has a certain antibacterial activity, CA, C-BF, and CP-1 have better antibacterial activity, but the antibacterial activity is not as good as the antimicrobial peptide KR-22, and aureomycin has a lower antibacterial effect. Good, but has a high killing effect on probiotics, and KR-22 has a weak inhibitory effect on probiotics. However, P-OG1 showed a dose-dependent effect, and the hemolysis rate and cytotoxicity increased with increasing concentration, and its safety was much lower than that of the antimicrobial peptide KR-22 (see Figure 3).
实施例3 、抗菌肽KR-22的溶血活性Example 3, hemolytic activity of antimicrobial peptide KR-22
从猪前腔静脉取血后,取肝素抗凝的10mL猪前腔静脉血液和10mL的RPMI1640培养基按照1:1混匀,将20mL稀释后的血液缓慢滴入10mL Ficoll-Paque 淋巴细胞分离液,保持界面清晰,待血液全部滴入分离液后,1500rpm离心15min,离心后,出现分层,最底层即红细胞,收集最底层红细胞。用1×PBS 溶液清洗红细胞,并重悬红细胞,在无制动状态下1000rpm离心10min,弃掉上清液,重复三次,直至上清液无色。将冲洗好的红细胞和 1×PBS按照 1:89的比例制成用于溶血率测定的红细胞工作液,即1%的红细胞工作液。After taking blood from the pig anterior vena cava, take 10mL of heparin-anticoagulated porcine anterior vena cava blood and 10mL of RPMI1640 medium and mix them evenly at a ratio of 1:1, and slowly drop 20mL of the diluted blood into 10mL of Ficoll-Paque lymphocyte separation medium , keep the interface clear, after all the blood is dripped into the separation solution, centrifuge at 1500rpm for 15min, after centrifugation, stratification occurs, the bottom layer is red blood cells, collect the bottom layer of red blood cells. Wash the erythrocytes with 1×PBS solution, resuspend the erythrocytes, centrifuge at 1000rpm for 10min without braking, discard the supernatant, and repeat three times until the supernatant is colorless. Prepare the red blood cell working solution for the determination of hemolysis rate by mixing the washed red blood cells and 1×PBS at a ratio of 1:89, that is, 1% red blood cell working solution.
将抗菌肽KR-22分别在96孔板上按照浓度梯度稀释,每孔10uL,终浓度为512、256、128、64、32、16、8、4 μg/mL,并将90uL红细胞工作液加入稀释好的抗菌肽孔中,同时设置阳性对照孔为1%的90uL红细胞工作液中加入 Triton X-100(终浓度为1%),阴性对照加入10uL 1×PBS,每个处理3个重复。将96孔板置于细胞培养箱中培养24h后,在无制动状态下1500rpm离心20min。小心吸取上清至新平底透明96孔培养板中,用酶标仪测定OD414nm和OD546nm下的吸光度,计算ΔOD值。红细胞溶血率的计算公式为:溶血率(%)=100%*(ΔOD试验-ΔOD阴性对照)/(ΔOD阳性对照-ΔOD阴性对照)。Dilute the antibacterial peptide KR-22 on the 96-well plate according to the concentration gradient, 10uL per well, the final concentration is 512, 256, 128, 64, 32, 16, 8, 4 μg/mL, and add 90uL red blood cell working solution In the diluted antimicrobial peptide wells, at the same time set positive control wells as 90uL red blood cell working solution with 1% Triton X-100 (final concentration 1%), and negative control wells with 10uL 1×PBS, and each treatment had 3 replicates. After the 96-well plate was placed in a cell culture incubator for 24 hours, it was centrifuged at 1500 rpm for 20 minutes without braking. Carefully pipette the supernatant into a new flat-bottomed transparent 96-well culture plate, measure the absorbance at OD414nm and OD546nm with a microplate reader, and calculate the ΔOD value. The formula for calculating the hemolysis rate of red blood cells is: hemolysis rate (%)=100%*(ΔOD test-ΔOD negative control)/(ΔOD positive control-ΔOD negative control).
抗菌肽 KR-22 的对猪血红细胞的溶血活性结果见图1。The hemolytic activity of antimicrobial peptide KR-22 on porcine red blood cells is shown in Figure 1.
如图1所示,在浓度为256μg/mL时,抗菌肽KR-22溶血率仍低于25%,说明抗菌肽KR-22的溶血率较低。As shown in Figure 1, when the concentration was 256 μg/mL, the hemolysis rate of antibacterial peptide KR-22 was still lower than 25%, indicating that the hemolysis rate of antimicrobial peptide KR-22 was low.
实施例4 、抗菌肽KR-22的细胞毒性Embodiment 4, the cytotoxicity of antimicrobial peptide KR-22
将分离纯化的外周围血单核细胞(PBMCs)用培养基RMPI1640稀释至1×106个/mL,按照每孔 90uL接种96孔板,同时设背景对照(100μL RMPI1640培养基),低水平对照孔(90μL细胞悬液+10μL PBS)和高水平对照孔(90μL细胞悬液+10μL 20%的TritonX-100)。将96孔板于37℃,5% CO2培养箱中静置培养 2h;加入10uL相应浓度的抗菌肽KR-22、KR-32、P-OG1和C-BF,使抗菌肽终浓度分别为 512μg/mL、256μg/mL、128μg/mL、64μg/mL、32μg/mL、16μg/mL、8μg/mL,每个处理6个重复。培养箱中培养 24h后,向阳性对照孔中加入10μL 20%的TritonX-100,并用移液器吹打混匀,继续培养15min;培养结束后,1500rpm 离心10min;离心后自各孔中小心吸取 60uL细胞上清转移到透明平底 96孔培养板相应孔中;每孔加入稀释好的LDH检测试剂30uL,室温避光震荡培养30min,酶标仪测定OD492nm、OD900nm,计算ΔOD值。Dilute the isolated and purified peripheral blood mononuclear cells (PBMCs) with medium RMPI1640 to 1 ×106 cells/mL, inoculate 96-well plate at 90uL per well, and set background control (100μL RMPI1640 medium) and low-level control at the same time Wells (90 μL cell suspension + 10 μL PBS) and high level control wells (90 μL cell suspension + 10 μL 20% TritonX-100). Incubate the 96-well plate at 37°C in a 5% CO 2 incubator for 2 hours; add 10 uL of corresponding concentrations of antimicrobial peptides KR-22, KR-32, P-OG1 and C-BF, so that the final concentrations of antimicrobial peptides are 512 μg/mL, 256 μg/mL, 128 μg/mL, 64 μg/mL, 32 μg/mL, 16 μg/mL, 8 μg/mL, 6 replicates for each treatment. After culturing in the incubator for 24 hours, add 10 μL of 20% TritonX-100 to the positive control well, blow and mix with a pipette, and continue to culture for 15 minutes; after the culture, centrifuge at 1500 rpm for 10 minutes; after centrifugation, carefully draw 60uL of cells from each well Transfer the supernatant to the corresponding wells of a transparent flat-bottomed 96-well culture plate; add 30uL of diluted LDH detection reagent to each well, and incubate with shaking at room temperature for 30min in the dark, measure OD492nm and OD900nm with a microplate reader, and calculate the ΔOD value.
LDH释放率按下面公式计算:LDH释放率(%)=100%*(ΔOD试验-ΔOD阴性对照)/(ΔOD阴性对照-ΔOD阳性对照)。The LDH release rate was calculated according to the following formula: LDH release rate (%)=100%*(ΔOD test-ΔOD negative control)/(ΔOD negative control-ΔOD positive control).
抗菌肽KR-22、P-OG1和C-BF对猪外周单核细胞的LDH释放率结果见图2。The results of LDH release rate of antimicrobial peptides KR-22, P-OG1 and C-BF on porcine peripheral mononuclear cells are shown in Figure 2.
如图2所示,在浓度低于128g/mL时,抗菌肽 KR-22猪外周单核细胞的LDH释放率小于15%,在浓度低于256μg/mL时,抗菌肽 KR-22猪外周单核细胞的LDH释放率小于20%,结果表明抗菌肽 KR-22的细胞毒性在三者中最低。As shown in Figure 2, when the concentration is lower than 128g/mL, the LDH release rate of the antimicrobial peptide KR-22 pig peripheral mononuclear cells is less than 15%, and when the concentration is lower than 256 μg/mL, the antimicrobial peptide KR-22 pig peripheral mononuclear cells The LDH release rate of nuclear cells was less than 20%, and the results showed that the cytotoxicity of the antimicrobial peptide KR-22 was the lowest among the three.
实施例5、抗菌肽KR-22发挥免疫调控作用治疗断奶仔猪腹泻Example 5: Antimicrobial Peptide KR-22 Plays Immunomodulatory Effect to Treat Diarrhea in Weaned Piglets
选取遗传背景相同、体重相近的21日龄杜长大腹泻断奶仔猪18头,随机分为3组,每组6头猪,腹腔注射三次,每天注射一次,生理盐水(对照组),20 mg乳酸环丙沙星(抗生素组),以及5 mg抗菌肽KR-22(抗菌肽KR-22组)。每天统计腹泻率和腹泻指数,腹泻率=[总腹泻头数/(试验猪头数×试验期)]×100%,腹泻指数评分标准, 0分:正常;1分:软便;2分:中度腹泻;3分:严重腹泻。结果如下表2、3所示。A total of 18 weaned piglets with the same genetic background and similar body weight were randomly divided into 3 groups, 6 pigs in each group, injected intraperitoneally three times, once a day, normal saline (control group), 20 mg lactic acid Ciprofloxacin (antibiotic group), and 5 mg antimicrobial peptide KR-22 (antimicrobial peptide KR-22 group). Diarrhea rate and diarrhea index were counted every day. Diarrhea rate = [total number of pigs with diarrhea / (number of test pigs × test period)] × 100%. Scoring standard for diarrhea index, 0 points: normal; 1 point: soft stool; 2 points: moderate Degree of diarrhea; 3 points: severe diarrhea. The results are shown in Tables 2 and 3 below.
表2.不同处理对仔猪腹泻率的影响Table 2. The effect of different treatments on the diarrhea rate of piglets
注:第0天表示注射之前,第1天为注射之后的第1天。每天记录两次腹泻情况(上午和下午)Note: Day 0 means before injection, and day 1 is day 1 after injection. Record diarrhea twice daily (morning and afternoon)
表3. 不同处理对仔猪腹泻指数的影响Table 3. Effects of different treatments on piglet diarrhea index
注:按照腹泻指数评分标准对每栏仔猪进行粪便评分,每天上午和下午各统计一次,取平均值。按照腹泻指数评分标准对每栏仔猪进行粪便评分,每天两次。(评分标准为:0分:正常;1分:软便;2分:中度腹泻;3分:严重腹泻)Note: According to the diarrhea index scoring standard, the feces of piglets in each column were scored, and the statistics were made once every morning and afternoon, and the average value was taken. The feces of piglets in each pen were scored according to the diarrhea index scoring standard twice a day. (The scoring standard is: 0 points: normal; 1 point: soft stool; 2 points: moderate diarrhea; 3 points: severe diarrhea)
如表2、3所示,注射后第三天,抗菌肽KR-22组方面,抗菌肽KR-22组断奶仔猪的腹泻率较对照组低25%,同时抗菌肽KR-22组断奶仔猪的腹泻指数较对照组低0.63,效果与抗生素相当,表明抗菌肽KR-22对断奶仔猪腹泻具有明显的缓解作用。As shown in Tables 2 and 3, on the third day after injection, in the antimicrobial peptide KR-22 group, the diarrhea rate of weaned piglets in the antimicrobial peptide KR-22 group was 25% lower than that in the control group. The diarrhea index was 0.63 lower than that of the control group, and the effect was equivalent to that of antibiotics, indicating that the antimicrobial peptide KR-22 had a significant alleviating effect on diarrhea in weaned piglets.
抗菌肽KR-22对断奶仔猪血清细胞因子的影响如下表4所示。The effect of antimicrobial peptide KR-22 on serum cytokines of weaned piglets is shown in Table 4 below.
表4. 抗菌肽KR-22对断奶仔猪血清细胞因子的影响Table 4. Effect of antimicrobial peptide KR-22 on serum cytokines of weaned piglets
注:炎症细胞因子(IL-6、IL-4和TNF-α)是指参与炎症反应的各种细胞因子,在一定范围内,数值越高,炎症情况越严重,在腹泻期间,仔猪炎症情况会随之加重。Note: Inflammatory cytokines (IL-6, IL-4, and TNF-α) refer to various cytokines involved in the inflammatory response. Within a certain range, the higher the value, the more serious the inflammation. During diarrhea, the piglets’ inflammation will increase accordingly.
细胞因子上,与对照组相比,抗菌肽KR-22方面,抗菌肽KR-22组断奶仔猪血清中IL-4和IL-6的含量分别降低了10%(P<0.05)和16.6%(P<0.05),但对TNF-α无显著影响。In terms of cytokines, compared with the control group, in terms of antimicrobial peptide KR-22, the contents of IL-4 and IL-6 in the serum of weaned piglets in the antimicrobial peptide KR-22 group decreased by 10% ( P <0.05) and 16.6% ( P < 0.05), but had no significant effect on TNF-α.
以上列举的仅为本发明的若干具体实施例,需注意的是,本发明不只局限于以上的实施例,可以有很多其他变形,包括抗菌肽KR-22序列的突变,改变氨基酸数量和种类,但不影响核心序列的功能特性。本领域的普通技术人员能从本发明公开的内容直接导出或联想到的所有变形,均应认为是本发明的保护范围。The above enumerations are only some specific examples of the present invention. It should be noted that the present invention is not limited to the above examples, and many other modifications can be made, including mutation of the antibacterial peptide KR-22 sequence, changing the number and types of amino acids, However, the functional properties of the core sequence are not affected. All deformations that can be directly derived or associated by those skilled in the art from the content disclosed in the present invention should be considered as the protection scope of the present invention.
序列表sequence listing
<110> 浙江大学<110> Zhejiang University
<120> 抗菌肽KR-22及其用途<120> Antimicrobial Peptide KR-22 and Its Application
<160> 5<160> 5
<170> SIPOSequenceListing 1.0<170> SIPOSequenceListing 1.0
<210> 1<210> 1
<211> 22<211> 22
<212> PRT<212> PRT
<213> 人工序列(Unknown)<213> Artificial sequence (Unknown)
<400> 1<400> 1
Lys Phe Phe Arg Lys Leu Trp Lys Arg Val Arg Arg Ala Ala Lys GluLys Phe Phe Arg Lys Leu Trp Lys Arg Val Arg Arg Ala Ala Lys Glu
1 5 10 151 5 10 15
Phe Phe Lys Trp Pro ArgPhe Phe Lys Trp Pro Arg
20 20
<210> 2<210> 2
<211> 30<211> 30
<212> PRT<212> PRT
<213> 金环蛇(Bungarus fasciatus)<213> Golden krait (Bungarus fasciatus)
<400> 2<400> 2
Lys Phe Phe Arg Lys Leu Lys Lys Ser Val Lys Lys Arg Ala Lys GluLys Phe Phe Arg Lys Leu Lys Lys Ser Val Lys Lys Arg Ala Lys Glu
1 5 10 151 5 10 15
Phe Phe Lys Lys Pro Arg Val Ile Gly Val Ser Ile Pro PhePhe Phe Lys Lys Pro Arg Val Ile Gly Val Ser Ile Pro Phe
20 25 30 20 25 30
<210> 3<210> 3
<211> 31<211> 31
<212> PRT<212> PRT
<213> 无指盘臭蛙(Rana grahami)<213> Fingerless Frog (Rana grahami)
<400> 3<400> 3
Gly Leu Trp Asp Thr Ile Lys Gln Ala Gly Lys Lys Phe Phe Leu AsnGly Leu Trp Asp Thr Ile Lys Gln Ala Gly Lys Lys Phe Phe Leu Asn
1 5 10 151 5 10 15
Val Leu Asp Lys Ile Arg Cys Lys Val Ala Gly Gly Cys Arg ThrVal Leu Asp Lys Ile Arg Cys Lys Val Ala Gly Gly Cys Arg Thr
20 25 30 20 25 30
<210> 4<210> 4
<211> 37<211> 37
<212> PRT<212> PRT
<213> 天蚕(Antheraea yamamai Guerin-Meneville)<213> Antheraea yamamai Guerin-Meneville
<400> 4<400> 4
Lys Trp Lys Leu Phe Lys Lys Ile Glu Lys Val Gly Gln Asn Ile ArgLys Trp Lys Leu Phe Lys Lys Ile Glu Lys Val Gly Gln Asn Ile Arg
1 5 10 151 5 10 15
Asp Gly Ile Ile Lys Ala Gly Pro Ala Val Ala Val Val Gly Gln AlaAsp Gly Ile Ile Lys Ala Gly Pro Ala Val Ala Val Val Gly Gln Ala
20 25 30 20 25 30
Thr Gln Ile Ala LysThr Gln Ile Ala Lys
35 35
<210> 5<210> 5
<211> 31<211> 31
<212> PRT<212> PRT
<213> 野猪(Sus scrofa)<213> Wild boar (Sus scrofa)
<400> 5<400> 5
Ser Trp Leu Ser Lys Thr Ala Lys Lys Leu Glu Asn Ser Ala Lys LysSer Trp Leu Ser Lys Thr Ala Lys Lys Leu Glu Asn Ser Ala Lys Lys
1 5 10 151 5 10 15
Arg Ile Ser Glu Gly Ile Ala Ile Ala Ile Gln Gly Gly Pro ArgArg Ile Ser Glu Gly Ile Ala Ile Ala Ile Gln Gly Gly Pro Arg
20 25 30 20 25 30
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710973506.4A CN107827966B (en) | 2017-10-19 | 2017-10-19 | Antibacterial peptide KR-22 and application thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710973506.4A CN107827966B (en) | 2017-10-19 | 2017-10-19 | Antibacterial peptide KR-22 and application thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107827966A CN107827966A (en) | 2018-03-23 |
CN107827966B true CN107827966B (en) | 2018-11-27 |
Family
ID=61648364
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710973506.4A Active CN107827966B (en) | 2017-10-19 | 2017-10-19 | Antibacterial peptide KR-22 and application thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107827966B (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112812159B (en) * | 2021-01-22 | 2022-11-08 | 杭州吾尾科技有限公司 | Yeast polypeptide derived from saccharomyces boulardii as well as preparation method and application thereof |
CN114773437B (en) * | 2022-04-14 | 2024-02-23 | 贵州医科大学 | Antibacterial peptide with broad-spectrum bactericidal activity and application thereof |
CN115925814B (en) * | 2022-07-16 | 2024-07-05 | 福建农林大学 | Antibacterial peptide RMR26 and preparation method and application thereof |
CN116178520B (en) * | 2023-03-09 | 2024-04-19 | 浙江大学医学院附属第一医院 | Cationic peptide and its application |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104628829A (en) * | 2015-02-06 | 2015-05-20 | 浙江大学 | Antibacterial peptide WY-21 and application thereof |
CN105175509A (en) * | 2015-10-19 | 2015-12-23 | 河南科技学院 | Antimicrobial peptide XYZ-1 and application thereof |
-
2017
- 2017-10-19 CN CN201710973506.4A patent/CN107827966B/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104628829A (en) * | 2015-02-06 | 2015-05-20 | 浙江大学 | Antibacterial peptide WY-21 and application thereof |
CN105175509A (en) * | 2015-10-19 | 2015-12-23 | 河南科技学院 | Antimicrobial peptide XYZ-1 and application thereof |
Non-Patent Citations (1)
Title |
---|
抗菌肽LL-37功能研究综述;喻钢等;《药物分析杂志》;20141231;第1890-1896页 * |
Also Published As
Publication number | Publication date |
---|---|
CN107827966A (en) | 2018-03-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107652359B (en) | Antibacterial peptide KR-32 and application thereof | |
CN104628829B (en) | Antibacterial peptide WY 21 and its application | |
CN107827966B (en) | Antibacterial peptide KR-22 and application thereof | |
CN104151415B (en) | A kind of natural antibacterial peptide Alligatorin4 and its application | |
CN110305222B (en) | A hybrid peptide with detoxification, anti-inflammation, anti-apoptosis, protection of intestinal barrier and promotion of wound healing and application thereof | |
TWI684642B (en) | Bacillus producing bacteriocin and application thereof | |
CN111333700A (en) | A kind of large yellow croaker whey acidic protein antibacterial peptide and its application | |
CN107252475B (en) | The application of natural host defense peptide Alligatorin4 | |
CN114853865B (en) | A modified antimicrobial peptide dsNCM1 and its application | |
CN104177485A (en) | Yangtze alligator antimicrobial peptide Alligatorin 6 and application thereof | |
CN112625108A (en) | Modified antibacterial peptide C-CM5 of tortoise green antibacterial peptide, and preparation method and application thereof | |
CN112625109A (en) | Modified antibacterial peptide C-CM6 of tortoise green antibacterial peptide, and preparation method and application thereof | |
CN104945484A (en) | Antibacterial peptide and preparation method and application thereof | |
CN110156875B (en) | Antibacterial peptide H5-p5 and its preparation method and application | |
CN112812159B (en) | Yeast polypeptide derived from saccharomyces boulardii as well as preparation method and application thereof | |
CN104163861A (en) | Reptile antibacterial peptide Alligatorin5 and applications thereof | |
CN111518187B (en) | Antibacterial peptide DN6NH2 and application thereof | |
CN111253474B (en) | Antibacterial peptide RG-27 and application thereof | |
CN111575243B (en) | Vibrio kansei phage and its application | |
CN113956340B (en) | A kind of antibacterial peptide RLR derived from sheep source and its preparation method and application | |
CN106632606A (en) | Antimicrobial lipopeptide bacaucin derivatives and application thereof in bacterial infection inhibition | |
CN115043925B (en) | Modified antibacterial peptide oNCM and application thereof | |
CN107261113B (en) | Application of natural host defense peptide Alligatorin5 | |
US10100086B2 (en) | Peptide and uses thereof | |
CN118995659B (en) | A Bacillus cereus aminomethyltransferase antimicrobial peptide BA14 and its application |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |